Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Adolescents with attention deficit hyperactivity disorder (ADHD) often develop substance use disorders (SUD). The purpose of this study is to evaluate the effectiveness of atomoxetine in treating adolescents dually diagnosed with ADHD and SUD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• DSM-IV diagnosis of ADHD

• Current or recent (within the three months prior to study entry) SUD, including marijuana and alcohol abuse

• ADHD CGI-S score of greater to or equal to 4

Exclusion Criteria:

• Any Unstable medical condition

• Recent history of intravenous drug use or cocaine dependence

• Currently abusing ecstasy, cocaine, gamma-hydroxybutyrate, methamphetamine, amphetamine, opioids, phencyclidine, or benzodiazepine

• Mental retardation or organic brain syndrome

• Currently psychotic or history of bipolar disorder

• Currently taking any psychotropic or anti-substance abuse disorder medications

• Current DSM-IV diagnosis of major depression, depressive disorder, or anorexia

• Pregnant or breastfeeding